34
Participants
Start Date
November 1, 2018
Primary Completion Date
April 5, 2023
Study Completion Date
April 8, 2024
Durvalumab
"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
Radiotherapy
"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
Radiotherapy (cohort 6 only)
"Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)"
Austin Health, Heidelberg
Princess Alexandra Hospital, Brisbane
Monash Health, Clayton
Lead Sponsor
Collaborators (1)
Olivia Newton-John Cancer Research Institute
OTHER
AstraZeneca
INDUSTRY
Austin Health
OTHER_GOV